Skip to content
TrackPodcasts
technologyNov 14, 202021:48pending

Covid Vaccine! Beyond Science via Press Release

About this episode

A vaccine for COVID seems to be (almost) here... or is it? What's hype/ what's real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19? Of course, this was just the first interim efficacy analysis -- so how close or far are we? What's the significance of the readout and case numbers? How do we put this (and related approaches, like Moderna's) in context of all the other (458!) programs in development? And how much should/ shouldn't we read into this news?

After all, it's "difficult to evaluate science via press release", as some say. So in this episode of 16 Minutes with a16z bio general partners Vineeta Agarwala and Jorge Conde in conversation with Sonal Chokshi, we break it all down: the math, the science, and the practical considerations -- from "vaccine efficacy" vs. efficiency, from cold chains to distribution, from patients to the system... as well as from the past, to present future of, vaccines.

references and readings cited in this episode:

Get every episode summarized

Each time 16 Minutes News by a16z publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

Covid Vaccine! Beyond Science via Press Release

16 Minutes News by a16z

0:00
21:48

More episodes

More from 16 Minutes News by a16z

View all episodes →